SecBot SecBot
8-K ·Filed Jun 15, 2026

PDSB

PDS Biotechnology Corp
BEARISH
Impact 7/10
Horizonweeks Processed5mo ago SEC0001140361-26-025207
Killer combo: Material agreement + unregistered equity (likely PIPE/convertible)
Actionable Insight ▼ Bearish

The $50M ATM represents massive dilution potential (85% of current market cap) and will likely be drawn down to repay the Yorkville note and fund operations. Monitor daily volume and ATM sales disclosures. The company must also resolve its Nasdaq deficiency by August 24, 2026, failure could accelerate distress. Short-term trading will be dominated by ATM mechanics and potential price pressure.

DirectionBearish
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$0.9600
T+0 close · Jun 15, 2026 · via day close
Latest settled
−67.16%
T+60 · $0.3153
Vs SPY
−68.16%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 16 $0.9600entry
  2. T+1 · 5mo ago −5.31%α −4.06% · $0.9090
  3. T+5 · 5mo ago −5.00%α −2.77% · $0.9120
  4. T+20 · 4mo ago −21.67%α −21.87% · $0.7520
  5. T+60 · 2mo ago −67.16%α −68.16% · $0.3153
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

PDS Biotechnology closed a $6M promissory note financing with Yorkville affiliate YA II PN, Ltd. (10% interest, 12-month maturity) and entered into a $50M at-the-market (ATM) equity offering program with Yorkville Securities and B. Riley Securities. The company also repaid its existing JGB debentures at a 103% premium. The ATM, which is 85% of current market cap, creates massive dilution risk and proceeds are required to first repay the Yorkville note.

Key Financial Metrics

Offering Size
$50.0M

Key Facts

  • Closed $6M promissory note with YA II PN, Ltd. at 96% of face value ($5.76M net), 10% interest, 12-month maturity
  • Issued warrant to purchase 2,158,274 shares at $1.1824 per share (out of the money vs. ~$1.06 current price)
  • Entered into $50M at-the-market (ATM) sales agreement with Yorkville Securities and B. Riley Securities
  • Repaid and terminated existing JGB Senior Secured Convertible Debentures at 103% of principal plus accrued interest
  • ATM proceeds must first be applied to amortization payments under the promissory note before working capital use
  • Company has a Nasdaq deficiency letter (Feb 25, 2026) that must be resolved by August 24, 2026

Financial Impact

Up to $50M in potential equity dilution via ATM on a $59M market cap; $6M promissory note at 10% interest; warrant adds 2.16M shares of overhang

dilutiondebtinterest expenseshare count

Risk Factors

  • Massive dilution from $50M ATM relative to $59M market cap
  • High-cost debt (10% interest) with 12-month maturity creates refinancing risk
  • Warrant overhang (2.16M shares) adds further dilution when exercised
  • Nasdaq deficiency letter unresolved, delisting risk if not cured by August 24, 2026
  • Yorkville affiliate involvement raises conflict-of-interest concerns (lender, ATM agent, warrant holder)

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
89% bullish (9 analysts)

Investment Themes

Documents Analyzed

This report is based on 7 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001140361-26-025207
Document: ef20076071_ex10-1.htm0001140361-26-025207
Document: ef20076071_8k.htm0001140361-26-025207
Document: ef20076071_ex5-1.htm0001140361-26-025207
Document: 0001140361-26-025207-index-headers.html0001140361-26-025207
Document: 0001140361-26-025207-index.html0001140361-26-025207
Document: 0001140361-26-025207.txt0001140361-26-025207

Track record

28 reports on PDSB

Performance horizon

6 of 13 bullish or bearish reports moved the stock their way by T+20. Best: +71.95% at T+20 after the Jul 22, 2026 report. 10 of 13 went positive at some point.

Filters
  1. Nov 13, 20263d ago Press Release Neutral 4/10 Entry $0.8726 Now $0.9240 +5.89% settles Dec 14
  2. Nov 12, 20264d ago SC 13D/A Neutral 4/10 Entry $0.9800 Now $0.9240 −5.71% settles Dec 11
  3. Nov 10, 20266d ago 8-K Neutral 4/10 Entry $1.03 Now $0.9240 −10.29% settles Dec 9
  4. Oct 20, 202627d ago 3 Neutral 2/10 Entry $1.24 Now $0.9240 −25.48% settles Nov 18
  5. Oct 20, 202627d ago 8-K Neutral 4/10 Entry $1.24 Now $0.9240 −25.48% settles Nov 18
  6. Oct 20, 202627d ago 8-K Neutral 3/10 Entry $0.9605 Now $0.9240 −3.80% settles Nov 17
  7. Oct 14, 20264w ago S-3 Bearish 7/10 Entry $1.30 to $0.9800 Now $0.9240 +28.92% ▲ +24.62% +22.71% vs SPY
  8. Oct 6, 20265w ago 8-K Neutral 3/10 Entry $1.05 to $1.41 Now $0.9240 −11.58% ▲ +34.93% +38.10% vs SPY
  9. Sep 22, 20267w ago 8-K Bullish 6/10 Entry $0.9100 to $0.9605 Now $0.9240 +1.54% ▲ +5.55% +6.11% vs SPY
  10. Sep 22, 20267w ago Press Release Bullish 7/10 Entry $0.9100 to $0.9605 Now $0.9240 +1.54% ▲ +5.55% +6.11% vs SPY
Showing 10 of 28

US Market Status

Market Closed · Opens in 6h 35m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 15, 2026